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Isoquinolinequinone N-oxides as anticancer agents effective 
against drug resistant cell lines 
Ryan D. Kruschel,a Alyah Buzid,a Udaya B. Rao Khandavilli,a Simon E. Lawrence,a Jeremy D.  Glennon 
a and Florence O. McCarthy *a 
The isoquinolinequinone (IQQ) pharmacophore is a privileged framework in known cytotoxic natural product families, 
caulibugulones and mansouramycins. Exploiting both families as a chemical starting point, we report on the structured 
development of an IQQ N-oxide anticancer framework which exhibits growth inhibition in the nM range across melanoma, 
ovarian and leukaemia cancer cell lines. A new lead compound (16, R6 = benzyl, R7 = H) exhibits nM GI50 values against 
31/57 human tumour cell lines screened as part of the NCI60 panel and shows activity against doxorubicin resistant tumour 
cell lines. An electrochemical study highlights a correlation between electropositivity of the IQQ N-oxide framework and 
cytotoxicity. Adduct binding to sulfur based biological nucleophiles glutathione and cysteine was observed in vitro. This new 
framework possesses significant anticancer potential.
1. Introduction 
The quinone moiety is a well-established anticancer framework 
found in the structures of many broad-spectrum anticancer 
agents approved by the U.S. Food and Drug Administration 
(FDA) for clinical use including doxorubicin, daunorubicin, 
mitomycin C and mitoxantrone. Quinone is a soft electrophile, 
allowing it to participate in adduct formation in vivo to sulfur 
based nucleophiles including the antioxidant glutathione, 
amino acid cysteine and DNA which can result in cancer cell 
death.1 In addition, redox cycling of the quinone moiety to the 
semi-quinone radical occurs in vivo and is a mechanism of 
cytotoxicity through generation of Reactive Oxygen Species 
(ROS) leading to cell cycle arrest and cancer cell death.2  
     The isoquinolinequinone (IQQ) pharmacophore is a 
privileged framework in known cytotoxic natural product 
metabolites, caulibugulones and mansouramycins.3,4 The 
mansouramycin series comprises of four members originally 
isolated from marine derived Streptomyces sp.  (Figure 1). 
Mansouramycins are characterised by having a secondary 
amine in the C(7) position and differ mainly on the pyridine ring 
substituents, namely a methyl, ester or indole moiety on C(3) 
and a methyl or proton on C(4). Analogous to the 
mansouramycin series the caulibugulone series comprises of six 
metabolites first isolated from the marine bryozoan caulibugula 
intermis. Caulibugulones A, B, C and D harbour an  
isoquinolinequinone framework as illustrated in Figure 1, 
whereas caulibugulones E and F comprise of an 
isoquinolineiminoquinone scaffold. Both natural product series  
contain halogens as in the case of mansouramycin B and 
caulibugulone B and C. 
 
 
 
 
 
 
 
 
Figure 1. Structures of known cytotoxic isoquinolinequinone 
caulibugulones and mansouramycins metabolites.  
 
     The mansouramycin family exhibit nM cytotoxicity across 
multiple cancers including ovarian, breast and melanoma. The 
most active analogue of the family is mansouramycin C (R3 = 
COOCH3) which exhibited an overall potency of 0.089 μM mean 
IC50 value across 36 tumour cell lines in a monolayer cell 
proliferation assay.4 In 2017 mansouramycin C was shown to 
selectively destroy cancer cells in preference to normal human 
cells through redox cycling mediated ROS generation and 
subsequent cell death by the opening of the mitochondrial 
permeability transition pore.5 In comparison with somatic cells, 
cancer cells generally experience higher oxidative stress, with 
an associated increased production of ROS. The introduction of 
a chemical species which amplifies ROS irreversibly damages 
the cancer cell leading to cell death. When a somatic cell is 
exposed to similar ROS augmentation, it is less likely to reach 
 R3 R4 R6   R6 R7 
A CH3 CH3 H  A H CH3 
B CH3 H Cl  B Br CH3 
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the threshold to trigger cell death due to the reduced basal ROS 
level.6 
     The caulibugulone series exhibit sub μM IC50’s against murine 
tumour cell line IC-2WT in an in vitro antiproliferative assay.3 A 
mechanistic study suggested that caulibugulone A generated 
modest levels of ROS to irreversibly inhibit Cdc25b leading to 
cell cycle arrest at the G1 and G2/M phases.7 Overexpression of 
Cdc25 phosphatases are observed in many cancer types 
including thyroid, breast, lymphoma and gastric.8 Interestingly, 
a similar mechanism of Cdc25 inhibition is suggested for 
established quinolinequinone based Cdc25 inhibitor, NSC 
663284 (Figure 2).9-11 
 
 
 
 
 
 
 
 
Figure 2. NSC 663284, an established Cdc25 inhibitor which shares a 
similar mechanism of action as caulibugulone family 
 
     ROS production is heavily entwined in the cytotoxicity of 
both mansouramycin and caulibugulone (and doxorubicin and 
quinones in general). Through chemical substitution the 
quinone can be made increasingly electropositive to more 
readily undergo redox cycling and become more susceptible to 
nucleophilic attack by biological nucleophiles.12-14 Delgado et al. 
identified that addition of an inductively electron withdrawing 
bromine to the C(6) or C(7) site of  IQQs generally result in more 
cytotoxic derivatives.15,16 Lending credence, further 
electrochemical studies suggested that the addition of bromine 
to the IQQ framework resulted in an increase in redox potential 
as measured by cyclic voltammetry, corresponding to a more 
electropositive species.15, 17 
     To date much work has been conducted to explore the 
chemical space around the IQQ framework to improve 
anticancer potential using mansouramycin and caulibugulone 
families as biological starting points. This synthetic work 
encompasses the amination and thiolation at the C(6) and C(7) 
positions, halogenation at the C(6) and C(7) positions, amino 
acid addition to the C(7) and C(6) positions, ring extension and 
dimer formation.15-26 Regioselective addition to the quinone 
moiety remains a problematic issue in current literature. 
Amination at the C(7) position is predominant in the literature 
due to regioselective addition of an amine employing cerium 
chloride as a directing Lewis acid.20,24 
     Herein we report on the expansion of literature knowledge 
of marine metabolite based isoquinolinequinone generation 
and their subsequent anticancer screening. We outline the 
generation of a novel IQQ N-oxide framework to probe the 
ability of the unexplored N-oxide moiety to alter the IQQ redox 
potential allowing the scaffold to possess greater cytotoxicity 
(Figure 3).  N-Oxides have been employed in drug development 
and discovered in antitumor natural product alkaloids including 
calothrixin A.27,28 The addition of the N-oxide has the potential 
to improve the pharmacological profile through reduction of 
metabolic oxidation, undergo redox cycling to produce free 
radicals and hydrogen bond within enzymatic active sites.29,30 In 
silico correlation studies were conducted employing the NCI60 
COMPARE analysis platform to identify a plausible mechanism 
of action. To confirm activity, adduct binding studies on novel 
analogues were performed to test their ability to bind to 
biological nucleophiles in vitro.  
 
 
 
 
 
Figure 3. This work describes the effect of N-oxide formation to alter 
the electronics of the quinone to improve its cytotoxicity. Amines are 
installed at the R6 and R7 positions to mimic natural products 
caulibugulones and mansouramycins. 
Results and Discussion 
     At the outset, the addition of an N-oxide moiety to the IQQ 
framework 2 imbues novelty and is proposed to remove 
electron density from the system to result in a more redox 
susceptible electropositive species. We subsequently set out to 
develop this template. 
 
Development of the Isoquinolinequinone N-oxide framework 
     The IQQ framework 2 was synthesised as a starting point 
through known literature methodology employing a one-pot 
silver mediated oxidation/Michael addition (Scheme 1).20 An 
IQQ N-oxide framework 3 was constructed utilising the m-CPBA 
oxidation of 2. The reaction was high yielding (70%), scalable to 
multigram quantities and carried out under ambient conditions.  
 
 
Scheme 1. Synthesis of the IQQ scaffold 2 and its subsequent oxidation 
with m-CPBA resulting in the novel IQQ N-oxide framework 3. 
 
     To compare the electrophilicity of IQQ frameworks 2 and 3, 
their redox potentials were measured by cyclic voltammetry 
(CV) in acetonitrile at room temperature using a platinum 
electrode and 0.1 M tetraethylammonium tetrafluoroborate as 
the supporting electrolyte and well defined quasi-reversible 
waves were observed. The first half-wave potentials (EI1/2) 
related to the formation of the semiquinone radical were 
evaluated from the resulting voltammograms obtained at a 
sweep rate of 100 mV s-1.15,20,31 The redox potential was 
measured to be -575 mV for IQQ 2, and -540 mV for IQQ N-oxide 
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3. IQQ N-oxide 3 exhibited a more positive redox potential, 
suggesting it is a more electropositive species. 
 
Regioselective Substitution to IQQ and IQQ N-oxide 
     Taking IQQ 2 and 3 we set out to map the anticancer activity 
at positions 6 and 7 by amine substitution and halogen 
incorporation. Methyl, butanol, ethyl morpholine and benzyl 
amines were chosen based on similarities to known 
caulibugulones and mansouramycins and to provide chemical 
diversity. This set of amines were tested on 2 with excellent 
regioselectivity and moderate to high yields (71-89%) resulting 
in aminated IQQs 4-7 (Scheme 2). 
 
 
 
 
 
 
 
Scheme 2. Regioselective substitution of IQQ framework and 
generation of fourteen novel analogues  
 
     To date regioselective amination to the IQQ scaffold has 
been inferred by 2D NMR, we present a single crystal X-ray 
structure of the ethylmorpholino substituted IQQ 5 (Figure 4). 
2D NMR studies of 5 revealed that the proton at C(6) correlates 
to C(8) carbonyl carbon (see SI), this is a common trend in the 
literature often used to confirm whether the C(7) or C(6) isomer 
is present.18 Ethyl morpholine IQQ 5 was developed to mimic 
known quinolinequinone NSC 663284, a potent irreversible 
inhibitor of Cdc25.   
 
 
 
 
 
Figure 4. Single crystal X-ray structure of ethyl morpholino 
isoquinolinequinone 5 confirming C(7) amine addition.  
 
     To mimic the natural product caulibugulone B, a bromine was 
introduced at the C(6) position post-amination employing NBS 
resulting in analogues 8-11 in moderate yields (56-75%). 
Bromination of the aminated IQQ species has been shown to 
increase cytotoxicity of the scaffold, partially due to the 
inductive effect bromine exhibits on the scaffold to make it 
more redox susceptible.17  
     Utilising the amination procedure as previously described, 
five IQQ N-oxides were furnished 12-16 (Scheme 2). No 
evidence of C(6) regioisomer formation was observed after 
column chromatography for analogues 12-14, however, 
addition of benzylamine resulted in the formation of two 
isomers, C(7) aminated 15 and C(6) aminated 16 which were 
isolated in 56% and 6% yield respectively.  
     The amination of IQQ N-oxide with benzylamine resulted in 
the generation of two regioisomers. To confirm regioselectivity 
2D NMR experiments were performed. Literature precedence 
for IQQ suggests that the C(5) carbonyl is considered to be more 
shielded than the C(8) carbonyl.16,18 For the C(7) benzylamine 
isomer 15 a three bond correlation of the C(6)H to the more 
deshielded C(8) carbonyl at 181.1 ppm can be observed (Figure 
5). For the C(6) benzylamine isomer 16 correlation of the C(7)H 
to the C(5) carbonyl at 179.1 ppm is noted. 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. HMBC correlations to deduce benzylamine addition site on the 
IQQ N-oxide framework. 
 
Preliminary Cytotoxicity Testing – NCI60 One-Dose Screening 
     An anticancer in vitro assay was conducted in collaboration 
with the National Cancer Institute 60 human tumour cell lines 
(NCI60) screening program. The initial methodology involves a 
one-dose screen at 10 μM concentration across a panel of up to 
60 human tumour cell lines.  
     The aminated IQQ series 4-7 exhibited minimal cytotoxicity 
across most cell lines, the most active being the benzylamine 
IQQ 7 with a mean tumour cell growth of 82.60% (Table 1). The 
addition of bromine to the IQQ framework significantly 
improves cytotoxicity across the series with an average 32% 
decrease in percentage cell growth. The bromo benzyl amine 
IQQ 11 exhibited potent cytotoxicity against tumour cell lines SK 
MEL-5, MCF-7, MALME-3M and OVCAR-4 exhibiting percentage 
cell growths -96.47%, -30.15%, -75.42% and -57.33% 
respectively. 
The IQQ N-oxide series 12-16 revealed a significantly 
reduced mean cell growth percentage in comparison to the 
aminated IQQ series as described in Table 1. Looking specifically 
at the C(6) bromine series 8-11 there is similar activity, which 
supports the N-oxide formation increasing the electropositivity 
HMBC Correlations (ppm) 
Entry 1H NMR  13C NMR 
15 C6(H) 5.75 C(8) 181.1 
16 C7(H) 5.79 C(5) 179.1 
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of the quinone, a similar effect observed by Ibacache et al 
through addition of bromine.17 
 
Table 1. Preliminary cytotoxic NCI60 one-dose cell growth percentage 
Series 
Com
pound 
  Growth of selected cell lines (%) 
M
ean (%
) 
G
row
th  
M
CF-7 
CO
LO
-205 
M
ALM
E-
3M
 
SK M
EL-5 
O
VCAR-3 
O
VCAR-4 
IQQ 
6H 
4 102 95 106 59 84 113 88 
5 97 81 96 65 86 95 81 
6 91 90 76 67 88 89 86 
7 83 76 79 -2 51 44 65 
IQQ 
6Br 
8 59 45 31 -27 -91 2 35 
9 93 82 56 37 71 13 74 
10 64 38 17 -3 -53 2 38 
11 22 -30 -12 -75 -96 -13 -57 
IQQ 
NOX 
6H 
3 -29 -59 -78 -88 -99 -9 -17 
12 61 57 8 -46 -48 7 26 
13 73 56 7 -13 49 5 35 
14 94 82 60 33 66 71 76 
15 20 -34 -9 -78 -85 1 -79 
7H 16 -35 -62 -37 -97 -98 -35 -95 
Cytotoxic data obtained from the preliminary NCI60 screen. Mean Growth % represents the 
mean cell growth of 60 cancer cell lines incubated with IQQ analogue at 10μM concentration. 
 
  Preliminary cytotoxicity studies on novel IQQ starting 
scaffold 3 at 10 μM revealed notable cytotoxic activities 
exhibiting a mean cell growth of -29.45%. The most responsive 
cancers identified across the series were melanoma (MALME-
3M, SK MEL-5), breast (MCF-7), colon (COLO 205) and ovarian 
(OVCAR-3, OVCAR-4). IQQ N-oxide 16 exhibited a lower mean 
cell growth of -35.10% in comparison to its C(7) regioisomer 15 
(19.75%). Compounds which achieve a pre-defined growth 
inhibition in a minimum number of cell lines progress to five-
dose anticancer screening. Four IQQ analogues 3, 11, 15 and 16 
were advanced to five-dose anticancer screening. 
 
Five-dose Anticancer Screening 
     Five-dose screening tests active compounds identified from 
the one-dose screen at 5 concentrations (ranging from  0.01 μM 
to 100 μM) against the full panel NCI60 cell line panel. The dose-
response curve generated enables the determination of three 
criteria, GI50 (drug concentration at which 50% of growth is 
inhibited), TGI (Total Growth Inhibition) and LC50 (drug 
concentration at which 50% of tumour cells are killed). IQQ’s 
exhibited GI50’s in the sub μM to nM range across multiple 
cancer cell lines (Table 2). The mean GI50’s from the four 
compounds 3, 11, 15 and 16 range from 0.91 μM to 2.93 μM, 
showing excellent potency. With a mean GI50 of 0.91 μM, the 
C(6) regioisomer 16 is more cytotoxic than the corresponding 
C(7) isomer 15 (Mean GI50 = 2.52 μM) and its’s precursor 3 
(Mean GI50 = 1.75 μM). This is a significant finding with respect 
to redefining the bioactivity of the isoquinolinequinones. 
A full NCI60 five-dose panel trend analysis was conducted using 
GI50 values as illustrated in Table 3. Conditional formatting was 
applied to the GI50 values of 3, 11, 15 and 16 to visually highlight 
common responsive cell lines. A high correlation of cancer cell 
responsiveness can be observed for the IQQ benzylamine 
analogues 11, 15 and 16. The most sensitive tumour cell lines 
were COLO-205, MALME-3M, OVCAR-3 and OVCAR-4, OVCAR-
8, MCF-7, MDA-MB-435 and MDA-MB-468. Interestingly the 
IQQ N-oxide framework 3 did not follow this trend, suggesting 
it may adopt an alternative or additional mechanism of 
cytotoxicity. 
 
Table 2. GI50’s of active IQQ benzyl amine analogues across multiple 
cancer cell lines 
Entry 3 11 15 16 
Mean GI50 1.75 2.93 2.52 0.91 
Mean LC50 28.30 42.14 52.99 23.86 
All figures are of μM concentration. Mean GI50 was calculated for 53 common human tumour 
cell lines. Mean LC50 was calculated for 50 common cancer cell lines. 
 
     Examples of excellent potency are seen for 3 with respect to 
leukaemia cell line CCRF-CEM, achieving a GI50 of 55.9 nM. The 
most responsive tumour cell lines against 16 were MDA-MB-468 
(259 nM), MCF-7 (290 nM), MALME-3M (134 nM), MDA-MB-
435 (208 nM), OVCAR-3 (272 nM). The common treatments for 
OVCAR-3 and OVCAR-4 human cancer cells are the quinone 
based doxorubicin as well as cisplatin and cyclophosphamide.32 
Responsiveness to quinone based anticancer agents is observed 
against OVCAR-3 by IQQ’s N-oxides 3, 15 and 16 with the most 
potent being 16.  
     IQQ’s 3 and 16 also exhibited nM growth inhibition against 
OVCAR 8 (339 nM and 484 nM respectively), a high grade serous 
ovarian adenocarcinoma, which has low survival rates.33 The 
doxorubicin resistant cell line NCI/ADR-RES is derived from the 
same individual and shares a large number of karyotypic 
abnormalities with OVCAR-8. NCI/ADR-RES is less responsive to 
3 (2.33μM) but is sensitive to 16 (535 nM). This cell line 
expresses a high level of multidrug resistance and P-
glycoprotein, but it is evident that the addition of the 
benzylamine unit to the 6-position overcomes doxorubicin 
resistance resulting in a GI50 for 16 less than 40 times than that 
of doxorubicin.34,35 
     The tumour cell lines marked in bold in Table 3 all harbour 
the TP53 gene mutation and are responsive in the range of <500 
nM.36 TP53 is a gene which provides instructions to make p53, 
a critical tumour suppressor and is mutated in approximately 
50% of human cancers and has been an attractive target for 
anticancer agents.37 There is an obvious correlation between 
the potency these compounds and the presence of mutant p53. 
 
Redox potential of benzylamine series 
     The addition of the N-oxide moiety to the IQQ benzylamine 
7 resulting in 15 results in an enhanced redox ability of the 
quinone unit observed through an increase in redox potential 
from -427 mV to -408 mV (Figure 6). The C(6) regioisomer 16  
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   3 11 15 16 
Le
uk
ae
m
ia
 CCRF-CEM 0.0559 3.11 2.98 0.793 
K-562 3.04 3.36 2.94 0.497 
MOLT-4 1.69 3.09 2.21 1.14 
RPMI-8226 2.07 3.24 2.61 1.52 
N
on
-s
m
al
l C
el
l L
un
g 
Ca
nc
er
 A549/ATCC 3.12 2.56 2.47 1.36 
EKVX 2.02 2.12 2.09 1.18 
HOP-62 0.744 3.12 3.1 1.67 
HOP-92 2.12 2.46 2.8 2.31 
NCI-H226 1.42 4.01 2.81 1.96 
NCI-H23 1.63 1.89 2.03 0.64 
NCI-H322M 1.68 3.45 2.59 1.08 
NCI-H460 2.72 2.94 2.74 0.731 
NCI-H522 1.66 2.25 2.45 1.2 
Co
lo
n 
Ca
nc
er
 
COLO-205 1.64 1.7 0.977 0.27 
HCC-2998 1.64 3.4 2.8 0.421 
HCT-116 0.945 2.5 2.47 0.305 
HCT-15 1.43 2.76 1.7 0.483 
HT-29 2.41 2.97 1.97 0.374 
KM12 1.99 2.93 2.4 0.653 
SW-620 1.54 3.39 3.12 0.385 
CN
S 
Ca
nc
er
 SF-268 2.05 3.46 2.81 1.48 
SF-295 1.78 3.04 2.6 1.09 
SF-539 1.8 2.85 2.29 1.13 
U251 1.48 2.74 2.46 1.34 
M
el
an
om
a 
LOX IMVI 1.44 2.45 2.72 0.36 
MALME-3M 1.53 1.47 0.617 0.134 
M14 1.78 2.06 1.97 0.729 
MDA-MB-435 1.79 1.86 1.81 0.208 
SK-MEL-2 1.89 2.52 2.63 1.21 
SK-MEL-28 1.96 5.79 4.63 2.21 
SK-MEL-5 1.14 1.47 1.23 0.249 
UACC-257 1.57 1.62 1.7 0.279 
UACC-62 1.63 1.41 1.8 0.316 
O
va
ria
n 
Ca
nc
er
 IGROV1 1.74 2.05 1.71 0.656 
OVCAR-3 0.314 2.27 0.613 0.272 
OVCAR-4 1.2 1.55 1.13 0.316 
OVCAR-5 1.76 3.11 2.58 1.4 
OVCAR-8 0.339 2.51 2.32 0.484 
NCI-ADR/RES 2.33 2.83 2.67 0.535 
Re
na
l C
an
ce
r 
786-0 2.07 4.65 3.68 2.33 
A498 3.58 4.48 4.72 1.39 
ACHN 1.9 3.08 2.73 1.13 
CAKI-1 1.95 5.66 2.84 0.972 
RXF 393 1.42 3.08 2.47 1.34 
SN12C 1.62 1.49 2.13 0.408 
UO-31 1.69 2.41 2.9 1.26 
Prostate DU-145 1.82 4.26 3.5 1.37 
  MCF7 1.55 1.3 1.65 0.29 
Br
ea
st
 C
an
ce
r 
MDA-MB-
231/ATCC 2.68 2.11 3.03 0.385 
HS 578T 2.84 10.8 7 1.9 
BT-549 1.72 4.08 4.19 1.49 
T-47D 1.97 2.26 1.88 0.346 
MDA-MB-468 0.946 1.1 1.3 0.259 
Table 3. Five-dose GI50 trend analysis of 3, 11, 15 and 16 against the full 
panel of human tumour cell lines. Red = most responsive cell lines, 
Green = least responsive cell line. Values are shown in μM.  
exhibits a more positive redox potential of -384 mV when 
compared to the C(7) isomer 15, and also exhibits a greater 
cytotoxicity in vitro. A similar observation is made by Delgado et 
al. where an amine at the 7-position of an isoquinolinequinone 
system has a greater electron donor capacity than an amine at 
the 6-position, resulting in differences in cytotoxicity.15 
 
 
 
 
 
 
Figure 6. The increasing half-wave potential (EI1/2) suggests a correlation 
to the increase in anticancer activity for 7, 15 and 16. 
 
COMPARE Analysis 
     COMPARE analysis is an in silico tool hosted by the National 
Cancer Institute whose function is to compare useful cytotoxic 
parameters identified in the five-dose screen such as the GI50, 
LC50 and TGI50 of novel analogues against parameters of vast 
libraries of known anticancer agents to provide insights into 
possible mechanisms of action. The correlation ranges from 0 
(no correlation) to 1 (full correlation). We chose the GI50 
parameter of the most cytotoxic IQQ N-oxides 3, 15 and 16 for 
COMPARE analysis (Table 4).  
     The GI50 data for IQQ N-oxide 3 correlated to antimetabolites 
2-deoxyuridine and nelarabine. GI50 data from 15 and 16 made 
significant correlations with many naphthazarin based 
compounds including (1S,3S)-austrocortirubin, tetrangulol, NSC 
658444 which undergo DNA damage through redox cycling and 
electrophilic DNA binding (Figure 7).39-42 Due to the similarity of 
human tumour cell responsiveness of both 15 and 16 as 
illustrated in Table 3, both compounds GI50 data correlated 
reasonably well together with a value of 0.725. In contrast, 
IQQ’s 15 and 16 correlated poorly to 3 as expected, 0.291 and 
0.2 respectively. 
     A direct in vitro cytotoxic comparison can be made with the 
fungal derived (1S,3S)-austrocortirubin which exhibits a GI50 of  
3.7 ± 0.6 μM against the human colon cancer cell line HCT116 
through inducing DNA damage.40 IQQ N-oxides 15 and 16 
exhibit GI50’s of 2.47 μM and 0.305 μM against HCT116 
respectively.  
 
Adduct formation studies to probe electrophilicity of 
Isoquinolinequinone N-oxide 
     As electrophilic species, quinones may be susceptible to 
glutathione, cysteine and DNA conjugation in vivo. A qualitative 
in vitro adduct binding assay was performed to test if binding to 
amino acids cysteine and serine, and the antioxidant 
glutathione (Table 5) would occur at 37 °C. IQQ 2 and IQQ N-
oxide 3 formed adducts with all nucleophiles screened. 
Interestingly upon benzylamine addition 7, no serine adduct 
was observed. The IQQ N-oxide benzylamine analogues 
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11,15,16 formed adducts with the thiol-based cysteine and 
glutathione, again no serine adduct was observed.   
 
Table 4. COMPARE analysis of IQQ N-oxides 3,15,16 
 
Entry Correlation Drug Mechanism of Action 
3 0.711 2-Deoxyuridine Nucleoside antimetabolite 
 0.675 Nelarabine Purine nucleoside analogue 
(DNA synthesis inhibition)38 
15 0.687 Tetrangulol DNA Intercalation. ROS 
Production39 
0.681 (1S,3S)-
Austrocortirubin 
Oxidative Stress (ROS). DNA 
double strand breaks40 
0.653 NSC 331757 Anthraquinone 
16 0.725 NSC 658444 DNA Damage. Halting Cell 
Cycle41,42 
0.705 (1S,3S)-
Austrocortirubin 
As Above 
0.686 Discorhabdin C-
dienol. TFA 
Farnesyltransferase enzyme, 
(HIF-1α), transcriptional co-
activator p300 inhibitor43 
0.672 NSC 331757 Anthraquinone 
                Please see supplementary information for drug structures. 
 
 
 
 
 
 
 
 
Figure 7. The highest correlations identified by COMPARE analysis were 
tetrangulol, (1S,3S)-austrocortirubin and NSC 658444 which all harbour 
the naphthazarin framework. 
 
Table 5. Binding IQQ analogues to biological nucleophiles at 37°C 
 = forms adduct,  = no adduct observed. Assay conditions: IQQ (2 mM) 
incubated with nucleophile (3 mM) in water/methanol at 37°C for 12 hours. The 
resulting mixture was qualitatively screened using LC/MS for the identification of 
the adducts. In all cases mono-adduct formation was observed. 
Experimental 
General Experimental  
     All solvents were distilled prior to use by the following 
methods: dichloromethane was distilled from phosphorus 
pentoxide, ethyl acetate was distilled from potassium 
carbonate, hexane was distilled prior to use. Organic phases 
were dried over anhydrous magnesium sulfate. All commercial 
reagents were procured from both international and local 
suppliers such as Fluorochem, Acros, Merck and Alpha Aesar 
and were used without further purification unless stated 
otherwise.  1H (300 MHz or 400 MHz) and 13C (75 MHz or 100 
MHz) NMR spectra were recorded on a Bruker Avance 300 or 
400 NMR  spectrometer. All spectra were recorded at 20 °C in 
deuterated dimethylsulfoxide (DMSO- d6) or deuterated 
chloroform (CDCl3) using tetramethylsilane (TMS) as an internal 
standard unless otherwise stated. Chemical shifts (δH and δC) 
are reported in parts per million (ppm) relative to the reference 
peak. The order of citation in parentheses is a) number of 
protons, b) multiplicity (s =singlet, bs = broad singlet, d = 
doublet, t = triplet, q = quartet, dd= doublet of doublet, quin. = 
quintet, sep. = septet, m = multiplet), c) coupling constants, 
(coupling constants (J) are reported in Hertz (Hz)). Infrared 
spectra were recorded as thin films on sodium chloride plates 
for oils or as potassium bromide (KBr) discs for solids on a Perkin 
Elmer Spectrum 100 FT-IR spectrometer or a Perkin Elmer 
Spectrum One FT-IR spectrometer. Nominal mass spectra were 
recorded on a Waters Quattro Micro triple quadrupole 
spectrometer (QAA1202) in ESI mode using 50% acetonitrile – 
water containing 0.1% formic acid as eluent. High resolution 
mass spectra (HRMS) were recorded on a Waters LCT Premier 
Time of Flight spectrometer (KD160) or a Waters Vion IMS mass 
spectrometer (SAA055K) in ESI mode using 50% acetonitrile – 
water containing 0.1% formic acid as eluent. Samples (max. 1 
mg) were dissolved in acetonitrile, water or 10% 
DMSO/acetonitrile. Melting points were measured on a uni-
melt Thomas Hoover capillary melting point apparatus and are 
uncorrected. Thin layer chromatography (TLC) was carried out 
on precoated silica gel plates (Merck 60 PF254). Visualisation was 
achieved by UV light detection (254 and 366 nm). Wet flash 
column chromatography was performed using Merck PF254 silica 
gel unless otherwise stated. Single-crystal X-ray analysis was 
performed on a Bruker APEX II DUO diffractometer at room 
temperature using graphite monochromatic Mo Kα (λ= 0.7107 
Å) radiation. All calculations and refinement were made using 
the APEX software, containing the SHELX suite of programs44 
and diagrams prepared with Mercury 3.10.45 All non-hydrogen 
atoms were located and refined with anisotropic thermal 
parameters. Hydrogen atoms were included in calculated 
positions or were located and refined with isotropic thermal 
parameters. 
 
     Methyl 1,3-dimethyl-5,8-dioxo-5,8-dihydroisoquinoline-4-
carboxylate (2). A suspension of 2,5-dihydroxyacetophenone 
(2.040 g, 13.41 mmol), silver(I) oxide (6.081 g, 26.24 mmol), 
methyl 3-aminocrotonate (1.620 g, 14.07 mmol) and 
magnesium sulfate (6.405 g) was stirred vigorously at room 
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temperature in dichloromethane (330 mL) resulting in a black 
suspension. The reaction mixture was stirred for 18 hours at 
room temperature until reaction completion, confirmed by TLC 
(1:1 ethyl acetate: hexane), resulting in a yellow solution with 
grey precipitate. The entire crude reaction mixture was 
concentrated under reduced pressure yielding a crude black 
solid which was subjected to flash column chromatography (9:1 
dichloromethane: ethyl acetate) yielding the product as a 
yellow solid (2.872 g, 88%). m.p. 121.0-123.0 °C (Lit. 120.0 – 
122.0 °C); νmax/cm-1 (KBr): 3028, 2954, 1726, 1679, 1663, 1568, 
1541, 1430, 1383, 1327, 1296, 1254, 1218, 1118, 1090, 871; δH 
(300 MHz, CDCl3): 2.62 [3H, s, C(3)CH3], 2.97 [3H, s, C(1)CH3], 
4.02 [3H, s, COO(CH3)], 6.95 [2H, s, C(6,7)CH]; m/z (ESI+): 246.2 
(M+H)+, 100%. 
     4-(Methoxycarbonyl)-1,3-dimethyl-5,8-dioxo-5,8-
dihydroisoquinoline 2-oxide (3). Methyl 1,3-dimethyl-5,8-
dioxo-5,8-dihydro-isoquinoline-4-carboxylate (0.211 g, 0.860 
mmol) was dissolved in dichloromethane (3 mL) with stirring 
resulting in a dark yellow solution. meta-Chloroperoxybenzoic 
acid (0.282 g, 1.634 mmol) was then added resulting in a 
transparent orange solution. The reaction was stirred at room 
temperature for 24 hours resulting in a dark orange solution 
with white precipitate. TLC analysis was undertaken at this point 
to ensure reaction completion (1:1 ethyl acetate: hexane). The 
entire reaction mixture was concentrated under reduced 
pressure yielding a crude orange solid. Column chromatography 
was performed on this crude material (0:1 ethyl acetate: hexane 
– 3:7 ethyl acetate: hexane) yielding the product as an orange 
solid, (0.150 g, 70%). m.p. 119.0 – 120.0 °C (degradation); 
νmax/cm-1 (KBr): 3069, 2952, 1743, 1662, 1436, 1375, 1331, 
1299, 1231, 1064, 853;  δH (400 MHz, CDCl3): 2.52 [3H, s, 
C(3)CH3], 2.97 [3H, s, C(1)CH3], 4.04 [3H, s, COO(CH3)], 6.97 [2H, 
d, J = 3.8 C(6,7)CH]; δC (100 MHz, CDCl3): 14.7, 16.2, 53.5, 122.2, 
124.9, 128.2, 137.3, 139.9, 151.0, 152.1, 166.2, 181.7, 184.3; 
m/z (ESI+): 262.2 (M+H)+, 100%, HRMS (ESI+): Exact mass 
calculated for C13H12NO5 262.0715. Found 262.0705. 
 
 
Typical procedure for amination 
A suspension of isoquinolinequinone (1 equivalent), cerium 
chloride heptahydrate (spatula tip, catalytic), 4-(2-
aminoethyl)morpholine (2 equivalents) in absolute ethanol (30 
mL) was stirred for 3-6 hours at room temperature. The 
consumption of the isoquinolinequinone was monitored using 
TLC. The reaction mixture was then concentrated under 
reduced pressure and was subjected to flash column 
chromatography (ethyl acetate: hexane). The product was 
isolated and was dried overnight under reduced pressure. An 
ethyl acetate/hexane recrystallisation was required on 
analogue 6 to form a solid.  
     Methyl-1,3-dimethyl-7-(methylamino)-5,8-dioxo-5,8-
dihydroisoquinoline-4-carboxylate (4). Amination methyl 1,3-
dimethyl-5,8-dioxo-5,8-dihydroisoquinoline-4-carboxylate 
(0.487 g, 1.99 mmol), by methylamine (33% solution in absolute 
ethanol) (0.51 mL, 4.10 mmol) yielding the product as a red 
solid, (0.407 g, 75%). m.p. 268.0 – 270.0 °C; νmax/cm-1 (KBr): 
3250, 1736, 1677, 1635, 1614, 1601 1564, 1503, 1423, 1271, 
1088, 846; δH (400 MHz, CDCl3): 2.59 [3H, s, C(3)CH3], 2.93 [3H, 
s, C(1)CH3], 2.94 [3H, d, J 4.4 Hz, NH(CH3)], 4.01 [3H, s, COOCH3], 
5.70 [1H, s, C(6)H], 6.18 [1H, bd, J 4.4 Hz, NH]; δC (75 MHz, 
CDCl3): 22.8, 25.9, 29.2, 52.9, 99.7, 120.0, 125.3, 138.3, 149.4, 
160.7, 161.0, 169.3, 180.1, 181.3; m/z (ESI+): 275.3 (M+H)+, 
100%; HRMS (ESI+): Exact mass calculated for C14H15N2O4 
275.1032. Found 275.1031. 
     Methyl-1,3-dimethyl-7-((2-morpholinoethyl)amino)-5,8-
dioxo-5,8-dihydroisoquinoline-4-carboxylate (5). Amination of 
methyl 1,3-dimethyl-5,8 dioxo-5,8-dihydroisoquinoline-4-
carboxylate (0.151 g, 0.616 mmol) with 4-(2-
aminoethyl)morpholine (0.160 g, 1.230 mmol) yielded the 
product as a bright red solid, (0.171 g, 74%). m.p. 150.0 – 153.0 
°C; νmax/cm-1 (KBr): 3324, 2947, 2830, 1744, 1672, 1628, 1610, 
1496, 1382, 1348, 1320, 1248, 1192, 1118, 1103; δH (300 MHz, 
CDCl3): 2.50 [4H, t, J 4.5 Hz, N(CH2) x2 ], 2.59 [3H, s, C(3)CH3], 
2.69 [2H, t, J 5.9 Hz, CH2(3’)], 2.95 [3H, s, C(1)CH3], 3.21 [2H, q, J 
5.6 Hz, CH2(2’)], 3.76 [4H, t, J 4.5, O(CH2) x2], 4.00 [3H, s, 
COO(CH3)], 5.69 [1H, s, C(6)H], 6.72 [1H, s, NH]; δC (100 MHz, 
CDCl3): 22.8, 26.0, 38.4, 52.9, 53.1 [2xCH2], 55.4, 66.8 [2xCH2], 
100.0, 120.1, 125.3, 138.3, 148.4, 160.6, 160.9, 169.4, 180.2, 
181.4; m/z (ESI+): 374.3 (M+H)+, 100%; HRMS (ESI+): Exact mass 
calculated for C19H24N3O5 374.1716. Found 374.1713. Single 
crystals were grown from ethanol. Crystals of (5) are 
monoclinic, space group P21/n, formula C19H23N3O5, M = 373.40, 
a = 6.8732(3) Å, b = 16.6383(7) Å, c = 16.3749(7) Å β = 
91.7080(10)°, U = 1871.77(14) Å3, F(000) = 792, m(Mo Ka) = 
0.097 mm-1, Rint  = 0.043, R(Fo)  = 0.042, for 3030 observed 
reflections with I > 2s(I), wR2(F2) = 0.124 for all 3863 unique 
reflections.  
     Methyl 7-[4-hydroxybutyl)amino]-1,3-dimethyl-5,8-dioxo-
5,8-dihydroisoquinoline-4-carboxylate (6). Amination of 
methyl 1,3-dimethyl-5,8-dioxo-5,8-dihydroisoquinoline-4-
carboxylate (0.501 g, 2.043 mmol), with 4-amino-1-butanol 
(0.350 mL, 4.08 mmol) yielded the product as an orange solid, 
(0.481 g, 71%). m.p. 103.0 – 105.0 °C; νmax/cm-1 (KBr): 3425, 
3239, 2951, 1703, 1678, 1628, 1614, 1566, 1515, 1437, 1380, 
1329, 1289, 1232, 1205, 1094. 1035; δH (300 MHz, CDCl3): 1.63-
1.74 [2H, m, NHCH2CH2], 1.76-1.87 [2H, quin., J 7.3 Hz, 
OCH2CH2], 2.59 [3H, s, C(3)CH3], 2.92 [3H, s, C(1)CH3], 3.23 [2H, 
q, J 6.5 Hz, OCH2], 3.72 [2H, t, J 7.0 Hz (NH)CH2], 4.01 [3H, s, 
O(CH3)], 5.71 [1H, s, C(6)H], 6.38 [1H, bs, NH]; δC (75 MHz, 
CDCl3): 22.6, 24.7, 26.0, 29.7, 42.5, 53.0, 62.1, 99.7, 120.0, 
125.3, 138.3, 148.5, 160.7, 161.0, 169.4, 180.1, 181.4; m/z 
(ESI+): 333.2 (M+H)+, 100%; HRMS (ESI+): Exact mass calculated 
for C17H21N2O5 333.1450. Found 333.1441. 
     Methyl-7-(benzylamino-1,3-dimethyl-5,8-dioxo-5,8-
dihydroisoquinoline-4-carboxylate (7). Amination of methyl 
1,3-dimethyl-5,8-dioxo-5,8-dihydroisoquinoline-4-carboxylate 
(0.301 g, 1.227 mmol) with benzylamine (0.260 mL, 2.473 
mmol) yielded the product as a dark orange solid, (0.381 g, 
89%). m.p. 165.0 – 167.0 °C; νmax/cm-1 (KBr): 3338, 2947, 1728, 
1673, 1632, 1609, 1567, 1512, 1276, 1205, 1091, 1077; δH (300 
MHz, CDCl3): 2.59 [3H, s, C(3)CH3], 2.93 [3H, s, C(1)CH3], 3.99 
[3H, s, COO(CH3)], 4.37 [2H, d, J 5.7 Hz, NH(CH2)], 5.76 [1H, s, 
C(6)H], 6.42 [1H, bs, NH], 7.24-7.41 [5H, m, aromatic]; δC (75 
MHz, DMSO-d6): 22.6, 26.0, 45.5, 52.8, 99.6, 121.0, 124.7, 127.6 
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[3xCH], 128.9 [2xCH], 137.5, 138.2, 149.9, 159.5, 159.9, 168.9, 
179.3, 181.7; m/z (ESI+): 351.2 (M+H)+, 100%; HRMS (ESI+): Exact 
mass calculated for C20H19N2O4 351.1345. Found 351.1343. 
     4-(Methoxycarbonyl)-1,3-dimethyl-7-(methylamino)-5,8-
dioxo-5,8-dihydroisoquinoline 2-oxide (12). Amination of 
methyl 4-(methoxycarbonyl)-1,3-dimethyl-5,8-dioxo-5,8-
dihydroisoquinoline 2-oxide (0.201 g, 0.769 mmol) with 
methylamine (33% solution in absolute ethanol) (15.0 mL, 1.21 
mmol) yielded the product as a dark red solid (0.067 g, 30%). 
m.p. 242.0 – 243.0 °C; νmax/cm-1 (KBr): 3260, 1738, 1682, 1635, 
1602, 1537, 1504, 1420, 1313, 1067; δH (400 MHz, CDCl3): 2.52 
[3H, s, C(3)CH3], 2.94 [3H, d, J 5.4 Hz, NHCH3], 2.98 [3H, s, 
C(1)CH3], 4.02 [3H, s, COOCH3], 5.68 [1H, s, C(6)H], 6.07 [1H, bs, 
NH]; δC (75 MHz, CDCl3): 15.0, 16.3, 29.3, 53.3, 100.0, 123.9, 
124.9, 128.3, 149.2, 151.62, 151.65, 167.0, 178.7, 181.0; m/z 
(ESI+): 291.3 (M+H)+, 100%; HRMS (ESI+): Exact mass calculated 
for C14H15N2O5 291.0981. Found 291.0985. 
     4-(Methoxycarbonyl)-1,3-dimethyl-7-((2-morpholinoethyl)-
amino)-5,8-dihydroisoquinoline 2-oxide (13). Amination of 4-
(methoxycarbonyl)-1,3-dimethyl-5,8-dioxo-5,8-dihydroiso-
quinoline 2-oxide (0.121 g, 0.463 mmol) with 4-(2-
aminoethyl)morpholine (0.132 g, 1.01 mmol) yielded the 
product as a red solid, (0.114 g, 64 %). m.p. 110.0 – 113.0 °C; 
νmax/cm-1 (KBr): 3336, 2944, 2822, 1733, 1694, 1623, 1313, 
1234, 1117, 1060; δH (300 MHz, CDCl3): 2.50 [4H, t, J 4.5 Hz, 
NCH2 x2 ], 2.52 [3H, s, C(3)CH3], 2.69 [2H, t, J 6.0 Hz, NCH2], 3.00 
[3H, s, C(1)CH3], 3.21 [2H, q, J 5.5 Hz, NHCH2], 3.75 [4H, t, J 4.5 
Hz, OCH2 x2], 4.02 [3H, s, COOCH3], 5.67 [1H, s, C(6)H], 6.65 [1H, 
s, NH]; δC (75 MHz, CDCl3): 15.0, 16.3, 38.5, 53.1 [CH2 x 2], 53.3, 
55.3, 66.8 [CH2 x 2], 100.3, 124.0, 124.9, 128.3, 148.3, 151.5, 
151.6, 167.0, 178.7, 181.0; m/z (ESI+):  390.2 (M+H)+, 100%; 
HRMS (ESI+): Exact mass calculated for C19H22N3O6 388.1509. 
Found 388.1503. 
     7-((4-Hydroxybutyl)amino)-4-(methoxycarbonyl)-1,3-
dimethyl-5,8-dioxo-5,8 dihydroisoquinoline 2-oxide (14). 
Amination of 4-(methoxycarbonyl) -1,3-dimethyl-5,8-dioxo-5,8-
dihydroiso-quinoline 2-oxide (0.302 g, 1.156 mmol) with 4-
amino-1-butanol (0.22 mL, 2.31 mmol) yielded the product as 
an orange solid, (0.126 g, 30 %). m.p. 70.0 – 72.0 °C; νmax/cm-1 
(KBr): 3373, 2949, 2869, 1737, 1687, 1609, 1541, 1314, 1284, 
1230, 1061; δH (300 MHz, CDCl3): 1.69 [2H, m, NHCH2CH2], 1.82 
[2H, m, OCH2CH2], 2.52 [3H, s, C(3)CH3], 2.98 [3H, s, C(1)CH3], 
3.23 [2H, q, J 6.0 Hz, OCH2], 3.72 [2H, t, J 5.7 Hz NHCH2], 4.02 
[3H, s, O(CH3)], 5.70 [1H, s, C(6)H], 6.31 [1H, bs, NH]; δC (75 MHz, 
CDCl3): 15.0, 16.3, 24.7, 29.6, 42.6, 53.2, 62.0, 100.0, 123.9, 
125.0, 128.2, 148.3, 151.61, 151.65, 167.0, 178.7, 181.1; m/z 
(ESI-):  347.3 (M-H)-, 70%; HRMS (ESI+): Exact mass calculated for 
C17H21N2O6 349.13941. Found 349.1393 
     7-(Benzylamino)-4-(methoxycarbonyl)-1,3-dimethyl-5,8-
dioxo-5,8-dihydroisoquinoline 2-oxide. Amination of 4-
(methoxycarbonyl)-1,3-dimethyl-5,8-dioxo-5,8-dihydroiso-
quinoline 2-oxide (0.181 g, 0.69 mmol) with benzylamine (0.15 
mL, 1.37 mmol) yielded two regioisomeric products: C(7) 
regioisomer (15): red/orange solid. (0.141 g, 56%). m.p. 160 - 
163°C; R/f 0.15 (ethyl acetate: hexane, 1:1); νmax/cm-1 (KBr): 
3324, 1742, 1692, 1605, 1542, 1511, 1311, 1225, 1064; δH (300 
MHz, CDCl3): 2.52 [3H, s, C(3)CH3], 2.99 [3H, s, C(1)CH3], 4.01 
[3H, s, COOCH3], 4.37 [2H, d, J 5.7 Hz, NHCH2], 5.75 [1H, s, 
C(6)H], 6.35 [1H, bs, NH], 7.27 – 7.39 [5H, m, aromatic]; δC (100 
MHz, CDCl3): 15.1, 16.3, 47.0, 53.3, 101.1, 123.9, 124.7, 127.6 
[CH x 2], 128.3, 128.4, 129.1 [CH x 2], 135.2, 148.0, 151.6, 151.7, 
166.9, 178.9, 181.1; m/z (ESI+): 367.3 (M+H)+, 100%; HRMS 
(ESI+): Exact mass calculated for C20H19N2O5 367.1288. Found 
367.12911. C(6) regioisomer (16): Orange solid. (0.0144 g, 6%), 
m.p. 79-80°C; R/f 0.4 (ethyl acetate: hexane, 1:1); νmax/cm-1 
(NaCl): 3334, 2923, 2852, 1739, 1671, 1616, 1574, 1516, 1453, 
1435, 1373, 1315, 1280, 1231, 1143, 1070, 834, 811, 738; δH 
(300 MHz, CDCl3): 2.48 [3H, s, C(3)CH3], 3.00 [3H, s, C(1)CH3], 
4.01 [3H, s, COOCH3], 4.34 [2H, d, J 5.7 Hz, NHCH2], 5.79 [1H, s, 
C(6)H], 6.02 [1H, bs, NH], 7.24 – 7.41 [5H, m, aromatic]; δC (75 
MHz, CDCl3): 14.7, 15.9, 46.8, 53.3, 103.7, 127.6 [CH x 2], 128.3, 
129.1 [CH x 2], 135.4, 146.2, 166.7, 179.1, 182.4; m/z (ESI+): 
367.3 (M+H)+, 60%; HRMS (ESI+): Exact mass calculated for 
C20H18N2O5 367.1288. Found 367.1287. 
 
Typical Bromination Procedure 
Aminated isoquinolinequinone (1 equivalent) was dissolved in 
methanol (15 mL). N-Bromosuccinimide (2 equivalents) was 
added portionwise over 1 minute with stirring. The reaction 
mixture was stirred for 1 hour at room temperature. TLC (100% 
ethyl acetate) was used to monitor reaction progress. After 
stirring, the solvent was removed under reduced pressure and 
was subjected to flash column chromatography (ethyl acetate: 
hexane). The isolated product was dried overnight under 
reduced pressure. 
     Methyl 6-bromo-1,3-dimethyl-7-(methylamino)-5,8-dioxo-
5,8-dihydroisoquinoline-4-carboxylate (8). Methyl 1,3-
dimethyl-7-(methylamino)-5,8-dioxo-5,8-dihydroisoquinoline-
4-carboxylate (0.152 g, 0.554 mmol) was brominated with N-
bromosuccinimide (0.131 g, 0.736 mmol) yielding the product 
as a dark red solid (0.125 g, 64%). m.p. 218.0 – 220.0 °C; νmax/cm-
1 (KBr): 3351, 1733, 1669, 1595, 1572, 1516, 1210, 1088; δH 
(400 MHz, CDCl3): 2.59 [3H, s, C(3)CH3], 2.91 [3H, s, C(1)CH3], 
3.47 [3H, d, J 5.6 Hz, NHCH3], 4.03 [3H, s, COOCH3], 6.48 [1H, bs, 
NH]; ]; δC (100 MHz, CDCl3): 22.9, 26.0, 29.5, 53.1, 119.2, 125.6, 
136.7, 136.8, 151.8, 161.05, 161.18, 168.8, 177.7, 179.6; m/z 
(ESI+):  353.0 (M+H)+, 5%, 355.0 (M+H)+, 5%; HRMS (ESI+): Exact 
mass calculated for C14H14N2O4Br 353.0137. Found 353.0123. 
     Methyl-6-bromo-1,3-dimethyl-7-((2-morpholinoethyl)-
amino)-5,8-dioxo-5,8-dihydroisoquinoline-4-carboxylate (9). 
Methyl-1,3-dimethyl-7-((2-morpholinoethyl)amino)-5,8-dioxo-
5,8-dihydroisoquinoline-4-carboxylate (0.305 g, 0.817 mmol) 
was brominated with N-bromosuccinimide (0.314 g, 1.764 
mmol) yielding the product as a bright red solid, (0.208 g, 56%). 
m.p. 195.0 – 196.0 °C;  νmax/cm-1 (KBr): 3193, 2963, 1730, 1682, 
1585, 1559, 1328, 1289, 1204, 1116, 1068; δH (300 MHz, CDCl3): 
2.54 [4H, bt, NCH2)x2], 2.58 [3H, s, C(3)CH3], 2.68 [2H, t, J 5.9 Hz, 
NHCH2CH2], 2.91 [3H, s, C(1)CH3], 3.77 [4H, t, J 4.2 Hz, O(CH2) 
x2)], 3.97 [2H, bq, J 5.2 Hz, NHCH2], 4.03 [3H, s, OCH3], 7.28 [1H, 
bs, NH]; δC (75 MHz, CDCl3): 22.8, 26.0, 41.1, 52.8, 53.1 [2C], 
56.3, 66.8 [2C], 119.5, 123.1, 125.5, 136.7, 146.2, 160.90, 
160.92, 168.8, 179.8, 183.1; m/z (ESI+): 452.1 (M+H)+, 90%, 
454.1 (M+H)+, 100%; HRMS (ESI+): Exact mass calculated for 
C19H23N3O5Br79 452.0821. Found 452.0803. 
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     Methyl-6-bromo-7-[(4-hydroxybutyl)amino]-1,3-dimethyl-
5,8-dioxo-5,8-dihydro-isoquinoline-4-carboxylate (10). 
Methyl-7-[(4-hydroxybutyl)amino]-1,3-dimethyl-5,8-dioxo-5,8-
dihydroisoquinoline-4-carboxylate  (0.152 g, 0.457 mmol) was 
brominated with N-bromosuccinimide (0.091 g, 0.511 mmol) 
yielding the product as a dark orange solid, (0.14 g, 75%). m.p. 
153.0 – 155.0 °C; νmax/cm-1 (KBr): 3538, 3281, 2926, 2878, 1721, 
1681, 1591, 1567, 1333, 1203, 1094; δH (300 MHz, CDCl3): 1.68 
[2H, m, NHCH2CH2], 1.82 [2H, m, OCH2CH2], 2.58 [3H, s, 
C(3)CH3], 2.90 [3H, s, C(1)CH3], 3.73 [2H, t, J 6.0 Hz NHCH2], 3.94 
[2H, q, J 6.7 Hz, OCH2], 4.02 [3H, s, OCH3], 6.55 [1H, bs, NH], 8.1 
[1H, bs, OH]; δC (75 MHz, CDCl3): 22.8, 25.9, 27.3, 29.3, 29.5, 
53.1, 62.1, 125.6, 125.8, 131.4, 136.8, 144.7, 161.0, 161.1, 
168.8, 177.2, 179.8; m/z (ESI+): 411.1 (M+H)+, 90%, 413.0 
(M+H)+, 100%; HRMS (ESI+): Exact mass calculated for 
C17H20N2O5Br79 411.0556. Found 411.0541. 
     Methyl 7-(benzylamino)-6-bromo-1,3-dimethyl-5,8-dioxo-
5,8-dihydroisoquinoline-4-carboxylate (11). Methyl 7-
(benzylamino-1,3-dimethyl-5,8-dioxo-5,8-dihydroisoquinoline-
4-carboxylate (0.122 g, 0.348 mmol) was brominated with N-
bromosuccinimide (0.063 g, 0.354 mmol) yielding the product 
as a red solid, (0.102 g, 70%). m.p. 154.0 – 155.0 °C; νmax/cm-1 
(KBr): 3344, 3023, 2954, 2921, 1732, 1677, 1588, 1566, 1400, 
1331, 1196, 1180; δH (300 MHz, CDCl3): 2.59 [3H, s, C(3)CH3], 
2.88 [3H, s, C(1)CH3], 4.03 [3H, s, O(CH3)], 5.08 [2H, d, J 5.8 Hz, 
NHCH2], 6.47 [1H, bs, NH], 7.29 – 7.44 [5H, m, Ar-H]; δC (75 MHz, 
CDCl3): 22.9, 25.9, 49.4, 53.1, 125.6, 127.7 [2C], 128.3, 129.1 
[2C], 131.3, 136.6, 137.1, 139.3, 148.2, 161.0, 161.1, 168.6, 
179.6, 180.0; m/z (ESI+): 429.1 (M+H)+, 90%, 431.1 (M+H)+, 
100%; HRMS (ESI+): Exact mass calculated for C20H18N2O4Br79 
429.0450 Found 429.0445 
 
Electrochemical Measurements 
Cyclic  voltammetry (CV) and square wave voltammetry (SWV) 
measurements of compounds 2, 3, 11, 15, 16 were performed 
at room temperature using a CHI1040 A electrochemical 
workstation (CH Instrument, Austin, USA). The electrochemical 
cell consists of a Pt working electrode (diameter of 2 mm, IJ 
Cambria Scientific Ltd, UK), a Pt wire counter electrode (Sigma-
Aldrich, Dublin, Ireland), and non-aqueous reference electrode 
(Ag/Ag+, BASi Analytical Instruments, West Lafayette, IN). A 0.1 
M solution of tetrabutylammonium tetrafluoroborate in 
acetonitrile (ACN) was used as supporting electrolyte.  The Pt 
electrode was polished using diamond slurry (1 µm) with wet 
MasterTex paper, followed by sonication in deionized water for 
5 min. The CVs were run in the potential range 0.0 to -1.2 V 
versus non-aqueous Ag/Ag+ and used to estimate half-wave 
potential E1/2. Well-defined quasi-reversible waves were 
observed for the compounds, the cathodic peak related to the 
reduction of quinone, and the anodic one due to its re-
oxidation. The first half-wave potential values, EI1/2 evaluated 
from the voltammograms obtained at a scan rate of 100 mVs−1.  
SWVs were used for double confirmation; amplitude (Esw) of 25 
mV, a potential increment (ΔE) of 4 mV and a frequency (f) of 5 
Hz. Stock solutions (5 mM) were prepared in ACN before use 
and working solutions were prepared by dilution of stock 
solution with the supporting electrolyte; 2 mM each of 2, 3, 7, 
and 15 and 3 mM of 16. 
 
Cancer Cell Growth Assays (NCI60 Screening) 
     One-dose study: Tested compounds were initially solubilised 
in DMSO, diluted into RPMI 1640 and 5% fetal bovine serum/L-
glutamine, and added to 96-well plates containing cell lines 
previously cultured for 24 h. After 48-h incubation, the media 
were removed, and the cells were fixed and stained with 
sulforhodamine B to determine overall percent growth/total 
protein content. Unbound dye was removed with five washes 
of 1% acetic acid, and the plates were allowed to air dry. The 
dye was then resolubilised in Tris buffer, and the colorimetric 
absorbance was measured (515 nm). Growth inhibition was 
measured relative to the response generated from proliferating 
cells cultured under identical conditions for 48 hrs. Data from 
one-dose experiments pertains to the percentage growth at 10 
μM. 
     Five-dose study: Serial 5 x 10-fold dilution from an initial 
DMSO stock solution was performed, prior to incubation at each 
individual concentration (10 nM, 100 nM, 1 μM, 10 μM and 100 
μM). Using seven absorbance measurements (time zero (Tz), 
control growth (C), and test growth in the presence of drug at 
the five concentration levels (Ti)), the percentage growth was 
calculated at each of the drug concentrations levels. Percentage 
growth inhibition was calculated as: [(Ti-Tz)/(C-Tz)] x 100 for 
concentrations for which Ti ≥ Tz, [(Ti-Tz)/Tz] x 100 for 
concentrations for which Ti < Tz. Three dose response 
parameters were calculated for each experimental agent. 
Growth inhibition of 50% (GI50) was calculated from [(Ti-Tz)/(C-
Tz)] x 100 = 50, which is the drug concentration resulting in a 
50% reduction in the net protein increase (as measured by 
Sulforhodamine B staining) in control cells during the drug 
incubation. The drug concentration resulting in total growth 
inhibition (TGI) was calculated from Ti = Tz. The LC50 
(concentration of drug resulting in a 50% reduction in the 
measured protein at the end of the drug treatment as 
compared to that at the beginning) indicating a net loss of cells 
following treatment was calculated from [(Ti-Tz)/Tz] x 100 = -50. 
Values were calculated for each of these three parameters if the 
level of activity was reached; however, if the effect was not 
reached or was exceeded, the value for that parameter was 
expressed as greater or less than the maximum or minimum 
concentration tested.46,47 
 
COMPARE analysis 
     COMPARE analysis was conducted using the private access 
system provided by the National Cancer Institute 
(https://dtp.cancer.gov/databases_tools/compare.htm). Seed 
compounds were analysed using a number of target sets: 
synthetic compounds, BEC referral set, mechanistic set, 
standard agents, marketed drugs and diversity set. While the 
minimum correlation was set to 0.4, correlations of less than 
0.65 were discounted. All other criteria were unchanged. The 
top 2-4 correlations between all target sets were chosen. 
Experiments that were carried out at different concentrations 
to the seed compound were ignored unless the concentration 
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deviated by ±0.1. COMPARE analysis was conducted solely on 
five dose data for compounds 3, 15 and 16.48 GI50 correlation 
between 15 and 16 was conducted using the ‘matrix compare’ 
function. 
 
Adduct Binding Study 
     Sample preparation: Quinones 2, 3, 7, 11, 15, 16 were 
dissolved in acetonitrile to make 2 mM solution individually 
(solution A). The biological nucleophiles (cysteine, glutathione 
and serine) were dissolved in water/methanol (1:1) resulting in 
a 3mM solution individually (Solution B).  
     Reaction Conditions: 50 μL of solution A, 50 μL of solution B 
and 0.9 mL of methanol were added to a HPLC vial and the HPLC 
vial was placed into a water bath at 37°C for 12 hours. The 
resulting mixture was qualitatively screened using LC/MS (see 
SI) for the identification of the adducts. In all cases mono-
adduct formation was observed. See supplementary 
information for full adduct binding study procedure. 
Conclusions 
     In summary, a new IQQ N-oxide framework 3 was developed 
which exhibited outstanding activity against the NCI60 panel of 
human tumour cell lines. We report the first single crystal X-ray 
structure confirmation of the C(7) amination of the IQQ seed 2, 
which had been previously been characterised with 2D-NMR 
methods. Through the generation of fourteen novel IQQ’s 
divided into three series (amino IQQs, brominated IQQ’s and 
IQQ N-oxides) it was revealed that the amino IQQ’s exhibited 
the poorest effects on cell growth at 10 μM concentration, 
however, upon substitution of the 6-position with bromine we 
observe a significant increase in cytotoxicity by 32% on average. 
As predicted by electrochemical studies, if bromine is removed 
and a N-oxide moiety is installed we observe equipotent activity 
between both series.  
     Employing cyclic voltammetry, we identified IQQ N-oxide 16 
as the most electropositive species in the benzylamine series, 
whereas benzylamine IQQ 7 the least electropositive. This data 
suggests a correlation exists between the increase in redox 
potential to an increase in cytotoxicity, indicating the electronic 
nature of the quinone moiety plays a role in the biological 
mechanism of action, a common trend for quinone based 
anticancer agents. Adduct formation studies revealed that IQQ 
frameworks 2 and 3 covalently bind to oxygen and sulfur based 
biological nucleophiles in vitro, but, once aminated with 
benzylamine, only sulfur based adducts were isolated.  
The benzylamine analogues 11, 15 and 16 were the most 
potent of the IQQ N-oxide series and were selected for five-dose 
NCI screening. The most potent analogue identified was the C(6) 
benzylamine IQQ N-oxide 16, a compound isolated as a minor 
product and exhibited nM GI50 values against 31/57 human 
tumour cell lines screened as part of the NCI60 panel. The most 
responsive cancers identified being ovarian, melanoma, breast 
and colon. IQQ N-oxide 16 is a promising lead for future 
structure activity relationship studies and exhibits an activity of 
535 nM against the doxorubicin resistant tumour cell line 
NCI/ADR-RES. 
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